Cwm LLC Has $205,000 Holdings in Organon & Co. (NYSE:OGN)

Cwm LLC raised its position in Organon & Co. (NYSE:OGN) by 8.3% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 14,217 shares of the company’s stock after purchasing an additional 1,087 shares during the period. Cwm LLC’s holdings in Organon & Co. were worth $205,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Invesco Ltd. boosted its position in shares of Organon & Co. by 23.7% during the 3rd quarter. Invesco Ltd. now owns 10,240,630 shares of the company’s stock valued at $177,777,000 after purchasing an additional 1,963,682 shares in the last quarter. Massachusetts Financial Services Co. MA grew its position in shares of Organon & Co. by 4.9% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 9,280,300 shares of the company’s stock worth $161,106,000 after buying an additional 436,034 shares during the period. Nordea Investment Management AB increased its stake in shares of Organon & Co. by 2,016.0% in the 4th quarter. Nordea Investment Management AB now owns 3,128,810 shares of the company’s stock valued at $44,648,000 after acquiring an additional 2,980,945 shares in the last quarter. LSV Asset Management lifted its position in shares of Organon & Co. by 9.0% during the 3rd quarter. LSV Asset Management now owns 3,031,852 shares of the company’s stock valued at $52,633,000 after acquiring an additional 251,400 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its stake in Organon & Co. by 7.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 2,385,177 shares of the company’s stock worth $41,407,000 after acquiring an additional 173,977 shares in the last quarter. 77.43% of the stock is owned by institutional investors.

Organon & Co. Trading Up 0.6 %

OGN opened at $19.61 on Friday. Organon & Co. has a 1-year low of $10.84 and a 1-year high of $24.08. The company has a market cap of $5.04 billion, a price-to-earnings ratio of 4.79, a PEG ratio of 0.92 and a beta of 0.81. The company’s fifty day moving average price is $18.19 and its two-hundred day moving average price is $15.77.

Organon & Co. (NYSE:OGN) last posted its earnings results on Thursday, February 15th. The company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.14. The company had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.55 billion. Organon & Co. had a net margin of 16.50% and a negative return on equity of 259.73%. As a group, equities analysts forecast that Organon & Co. will post 4.1 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 13th. Stockholders of record on Monday, May 13th will be issued a $0.28 dividend. The ex-dividend date of this dividend is Friday, May 10th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 5.71%. Organon & Co.’s dividend payout ratio is presently 27.38%.

Analyst Upgrades and Downgrades

Several research firms have weighed in on OGN. Piper Sandler lifted their price target on shares of Organon & Co. from $22.00 to $24.00 and gave the company an “overweight” rating in a research note on Monday, April 29th. The Goldman Sachs Group boosted their target price on Organon & Co. from $18.00 to $20.00 and gave the company a “neutral” rating in a research report on Friday.

Insider Activity at Organon & Co.

In related news, insider Kirke Weaver purchased 2,720 shares of the stock in a transaction that occurred on Thursday, February 22nd. The stock was acquired at an average cost of $18.36 per share, with a total value of $49,939.20. Following the transaction, the insider now owns 15,181 shares of the company’s stock, valued at approximately $278,723.16. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.17% of the stock is owned by insiders.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.